These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31331574)

  • 1. Combination therapy with interferon beta-1a and sesame oil in multiple sclerosis.
    Faraji F; Hashemi M; Ghiasabadi A; Davoudian S; Talaie A; Ganji A; Mosayebi G
    Complement Ther Med; 2019 Aug; 45():275-279. PubMed ID: 31331574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon β-1a and Atorvastatin in the Treatment of Multiple Sclerosis.
    Ghasami K; Faraji F; Fazeli M; Ghazavi A; Mosayebi G
    Iran J Immunol; 2016 Mar; 13(1):16-26. PubMed ID: 27026043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism of sesame oil in ameliorating experimental autoimmune encephalomyelitis in C57BL/6 mice.
    Ghazavi A; Mosayebi G
    Phytother Res; 2012 Jan; 26(1):34-8. PubMed ID: 21538630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.
    Brod SA; Marshall GD; Henninger EM; Sriram S; Khan M; Wolinsky JS
    Neurology; 1996 Jun; 46(6):1633-8. PubMed ID: 8649562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Less Frequent and Less Severe Flu-Like Syndrome in Interferon Beta-1a Treated Multiple Sclerosis Patients with at Least One Allele Bearing the G>C Polymorphism at Position -174 of the IL-6 Promoter Gene.
    Bertoli D; Serana F; Sottini A; Cordioli C; Maimone D; Amato MP; Centonze D; Florio C; Puma E; Capra R; Imberti L
    PLoS One; 2015; 10(8):e0135441. PubMed ID: 26285213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta1a or glatiramer acetate compared with untreated patients.
    Jansson A; Ernerudh J; Kvarnström M; Ekerfelt C; Vrethem M
    Mult Scler; 2003 Oct; 9(5):440-5. PubMed ID: 14582766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.
    Ozenci V; Kouwenhoven M; Huang YM; Kivisäkk P; Link H
    Clin Exp Immunol; 2000 Apr; 120(1):147-53. PubMed ID: 10759776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of cytokine levels in multiple sclerosis patients and their relevance with patients' response to Cinnovex.
    Taheri M; Ghafouri-Fard S; Solgi G; Sayad A; Mazdeh M; Omrani MD
    Cytokine; 2017 Aug; 96():138-143. PubMed ID: 28399486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell interleukin-6 receptor binding in interferon-beta-1b-treated multiple sclerosis patients.
    Bongioanni P; Lombardo F; Moscato G; Mosti S; Meucci G
    Eur J Neurol; 2000 Nov; 7(6):647-53. PubMed ID: 11136350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.
    Sørensen PS; Sellebjerg F; Lycke J; Färkkilä M; Créange A; Lund CG; Schluep M; Frederiksen JL; Stenager E; Pfleger C; Garde E; Kinnunen E; Marhardt K;
    Eur J Neurol; 2016 May; 23(5):861-70. PubMed ID: 26848561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
    Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b.
    Ramirez-Ramirez V; Macias-Islas MA; Ortiz GG; Pacheco-Moises F; Torres-Sanchez ED; Sorto-Gomez TE; Cruz-Ramos JA; Orozco-Aviña G; Celis de la Rosa AJ
    Oxid Med Cell Longev; 2013; 2013():709493. PubMed ID: 23861993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis.
    Ossege LM; Sindern E; Patzold T; Malin JP
    Int Immunopharmacol; 2001 Jun; 1(6):1085-100. PubMed ID: 11407304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis.
    Salama HH; Kolar OJ; Zang YC; Zhang J
    Mult Scler; 2003 Feb; 9(1):28-31. PubMed ID: 12617264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG).
    Rudick RA; Simonian NA; Alam JA; Campion M; Scaramucci JO; Jones W; Coats ME; Goodkin DE; Weinstock-Guttman B; Herndon RM; Mass MK; Richert JR; Salazar AM; Munschauer FE; Cookfair DL; Simon JH; Jacobs LD
    Neurology; 1998 May; 50(5):1266-72. PubMed ID: 9595973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin Does Not Affect Nitric Oxide Generation Increased by Sesame Oil in Obese Zucker Rats.
    Cebova M; Rehakova R; Kosutova M; Pechanova O
    Oxid Med Cell Longev; 2018; 2018():5413423. PubMed ID: 30245774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response.
    Balasa R; Maier S; Voidazan S; Hutanu A; Bajko Z; Motataianu A; Tilea B; Tiu C
    CNS Neurol Disord Drug Targets; 2017; 16(1):93-101. PubMed ID: 27306062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon beta-1b increases interleukin-10 in a model of T cell-microglia interaction: relevance to MS.
    Chabot S; Yong VW
    Neurology; 2000 Nov; 55(10):1497-505. PubMed ID: 11094104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment.
    Ozenci V; Kouwenhoven M; Huang YM; Xiao B; Kivisäkk P; Fredrikson S; Link H
    Scand J Immunol; 1999 May; 49(5):554-61. PubMed ID: 10320650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.